Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Idiopathic Membranous Nephropathy
NCT01508468Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2012
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in idiopathic membranous nephropathy (IMN), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2012; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT01508468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508468.